Octarine Bio ApS (“Octarine” or “the company”), a synthetic biology company developing biosynthetic platforms for cannabinoids, psychedelics and their novel improved derivatives, today announced it has extended its seed round financing, closed in November 2020, with an additional $1.2 million USD due to significant demand from new and existing investors, bringing the total amount raised by the…


Previous articleNova Mentis Upgrades U.S. Listing to the OTCQB Venture Market
Next articleAion Therapeutic Files 4 New Patent Applications (Including for the Treatment of Human Cancers)